

# NOF CORPORATION

DDS DEVELOPMENT DIVISION

YEBISU GARDEN PLACE TOWER

20-3, EBISU 4-CHOME, SHIBUYA-KU, TOKYO 150-6019 JAPAN

TEL. +81-3-5424-6741 FAX. GIII +81-3-5424-6769

<http://www.nof.co.jp/dds> E-mail: [ddsinfo@nof.co.jp](mailto:ddsinfo@nof.co.jp)



May 20, 2013

## **NOF and NanoCarrier Co., Ltd. have a non-exclusive sales license agreement for nucleotide delivery polymer.**

TOKYO, Japan, May 20th, 2013 --- NOF CORPORATION announced that NOF entered into a non-exclusive, world-wide sale license agreement with NanoCarrier Co., Ltd. (Tokyo, Japan) based on the current exclusive, sublicense-available license agreement for gene therapeutics market using functional protein expressed gene. Therefore, NOF manufacture and sell NanoCarrier's patented polymer for research purpose only on a global basis.

This technology, developed by Professor Kazunori Kataoka of the University of Tokyo, shows that it is the nano-micelle particle technology encapsulated into polymer-ion complex with anionic charged oligonucleotide such as siRNA etc using cationic poly-amino acid derivatives as PEG-P[Asp(DET)].

This agreement enables NOF to supply reagents of the technology for oligonucleotide pharmaceutical development like siRNA therapeutics through our global sales network.

### About NanoCarrier Co., Ltd.

NanoCarriers key business objective is to deliver new pharmaceuticals primarily in the area of cancer to society through the use of micellar nanoparticle technology as core technology developed based on nanotechnology, which originates in Japan. NanoCarrier is focusing particularly on cancer therapy, in which there is a pressing need for more effective therapies. We are strongly committed to research and development through which we strive to develop cutting-edge pharmaceuticals to meet the needs of many patients suffering from cancer.

Conventional anticancer agents show similar cytotoxic effects on cancerous and normal cells. The administration of these agents generally causes adverse reactions because it is distributed to the entire body, affecting normal cells as well. Although prophylactic medications can control adverse reactions to some extent, they are often difficult to avoid altogether, and sometimes limit the use of chemotherapy. NanoCarriers pharmaceutical products, using the micellar nanoparticle technology, are expected to accumulate more in cancerous lesions, thereby reducing drug distribution to normal cells, and reducing the occurrence of adverse reactions.

### About NOF CORPORATION

As an integrated chemical manufacturing featuring diverse activities from " Biosphere to Outer Space", NOF CORPORATION is a specialty fine chemical company and widely known as Drug Delivery System (DDS) products supplier such as Activated PEG, phospholipids, highly purified Polysorbate 80 and other novel excipients for pharmaceutical fields. As the worldwide leader in DDS, NOF supplies these products to rapidly growing areas driven by technological innovation to antibody, protein, peptides, RNA/DNA, aptamer, oligonucleotides, enzyme and novel small molecules. For more information, please visit [www.nof.co.jp/dds](http://www.nof.co.jp/dds).